AbbVie will not be pursued any further by the US government over allegations that it used 'sham' litigation to keep competition to its AndroGel testosterone replacement product off the market.

2-Year U.S. Treasury Note Continuous Contract $103.445 0.008 0.01% 5-Year U.S. Treasury Note Continuous Contract $107.531 0.023 0.02% 10-Year U.S. Treasury Note Continuous Contract $109.938 0.031 ...

billboard hot 100™ the week’s most popular current songs across all genres, ranked by streaming activity from digital music sources tracked by luminate, radio airplay audience impressions as ...

Our ninth annual ranking of independent advisory companies is based on assets managed by the firms, growth, technology spending, succession planning, and other metrics. For the first time, Barron ...